Telix Pharmaceuticals (ASX:TLX) and partner ARTMS have announced they have successfully produced Telix's prostate cancer imaging product, TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11).

Australian seed-to-patient medicinal cannabis producer Cannatrek has announced it will supply medicinal cannabis products to LYPHE Group in support of Project TWENTY21, Europe’s first and largest national medical cannabis registry.

Health minister Greg Hunt has announced $20 million in funding for two new medical research centres that will focus on producing rapid improvements in the prevention and treatment of diabetes and cardiovascular disease.

As the country returns after the festive break and the realities of ‘COVID-normal’ and the respective New Year’s resolutions settle on us, AusBiotech starts the year focused on leadership in policy, and a resolution to continue committed advocacy for innovation in life sciences.

Pharmaxis (ASX:PXS) has received a US$7 million milestone payment from its US licensee Chiesi following the recent FDA approval of BRONCHITOL (mannitol) for the treatment of cystic fibrosis.

Boehringer Ingelheim has become the first pharmaceutical company to partner with Google in quantum computing with a three-year agreement and a newly established Quantum Lab of Boehringer Ingelheim.

US-based BIO has secured a preliminary injunction blocking the adoption of the 'most favoured nation' pricing policy for a key US government prescription medicine program.

Nyrada (ASX:NYR) has reported what it describes as "encouraging efficacy results" from its cholesterol-lowering drug program that is directed at developing an oral PCSK9 inhibitor treatment. 

2020 has been an unforgettable year, with the biotech community’s strong contribution to the global healthcare system and to Australia’s economy shining brightly through the many challenges being faced professionally and personally.